Get the Stockscreener App
2.2048
1.76%
-0.0652
Vyome Holdings Inc stock is traded at $2.2048, with a volume of 1,250.
It is down -1.76% in the last 24 hours and down -33.63% over the past month.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.
See More
Previous Close:
$2.27
Open:
$2.2525
24h Volume:
1,250
Relative Volume:
0.00
Market Cap:
$15.81M
Revenue:
$2.43M
Net Income/Loss:
$-11.03M
P/E Ratio:
0.0346
EPS:
63.6476
Net Cash Flow:
$-3.75M
1W Performance:
-2.19%
1M Performance:
-33.63%
6M Performance:
-56.87%
1Y Performance:
+0.00%
1-Day Range:
$2.2525
$2.2525
1-Week Range:
$2.0973
$2.39
52-Week Range:
$1.75
$12.87
Vyome Holdings Inc Stock (HIND) Company Profile
Name
Vyome Holdings Inc
Sector
Industry
Phone
949-429-6680
Address
1001 CALLE AMANECER, SAN CLEMENTE
Compare HIND vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HIND
Vyome Holdings Inc
|
2.2525 | 15.93M | 2.43M | -11.03M | -3.75M | 63.65 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Vyome Holdings Inc Stock (HIND) Latest News
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase - Business Wire
Vyome Holdings, Inc.: Fundamental Analysis and Financial Ratings | H1O | US92943X1046 - marketscreener.com
Vyome Holdings Reports Positive Phase 2 Clinical Results for VT-1953 Topical Gel in Malignant Fungating Wounds and Acne Treatment – 2026 Company Overview and Pipeline Update - Minichart
Vyome Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Vyome 10-K: $0.32M Revenue, $(4.86) Loss per Share - TradingView
Vyome (HIND) versus Its Competitors Critical Analysis - Defense World
Head-To-Head Comparison: Vyome (HIND) versus The Competition - Defense World
Vyome (HIND) vs. Its Rivals Head to Head Contrast - Defense World
Vyome (HIND) & The Competition Head to Head Analysis - Defense World
Reviewing Vyome (HIND) and Its Rivals - Defense World
HIND Technical Analysis & Stock Price Forecast - Intellectia AI
RSLS SEC FilingsReShape Lifesciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Vyome (HIND) versus Its Rivals Financial Analysis - Defense World
Analyzing Vyome (HIND) & Its Peers - Defense World
Vyome (HIND) & Its Peers Financial Survey - Defense World
Critical Comparison: Vyome (HIND) versus The Competition - Defense World
Financial Contrast: Vyome (HIND) & The Competition - Defense World
HIND Should I Buy - Intellectia AI
Vyome’s Livechain Acquires Humanyze to Expand AI HR Analytics - TipRanks
Vyome Holdings Unit LiveChain to Acquire $5.8M Humanyze Notes, Issuing 25% Equity to Remus - TradingView
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company - 01net
Livechain completes acquisition of senior, secured debt of Humanyze - marketscreener.com
Reviewing Vyome (HIND) and The Competition - Defense World
Head to Head Review: Vyome (HIND) and Its Rivals - Defense World
Comparing Vyome (NASDAQ:HIND) and Nanovibronix (NASDAQ:FEED) - Defense World
Vyome Therapeutics2026 Latest Shareholding - Tracxn
Reviewing Vyome (HIND) & The Competition - Defense World
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity - Bluefield Daily Telegraph
Critical Survey: Vyome (HIND) & Its Competitors - Defense World
Vyome (HIND) versus Its Competitors Financial Analysis - Defense World
Analyzing Vyome (HIND) & Its Competitors - Defense World
HIND Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vyome Reports Positive Phase 2 Data for VT-1953 Gel - TipRanks
Vyome Holdings, Inc. Reports Positive Phase 2 Results for VT-1953 - TradingView
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months - The Joplin Globe
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Vyome raises $5.29 million to fund phase 3 trial of MFW treatment - Investing.com Nigeria
Vyome raises $5.29 million to fund phase 3 trial of MFW treatment By Investing.com - Investing.com South Africa
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results - BioSpace
Vyome capitalizes all VT-1953 funding requirements for initial phase 3 results - marketscreener.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Penny Stocks To Follow Now – January 27th - Defense World
Recommendations-Union Budget FY27, Vyome Holdings, Inc. - Medical Buyer
Vyome Holdings Highlights VT-1953 Market Potential Analysis - TipRanks
Vyome Holdings, Inc Announces Key Findings on VT-1953 - TradingView
Vyome Holdings Stock Tumults After Strategic Moves in Europe - timothysykes.com
Hindustan Diverges: Financial Snapshot Paints Varied Picture - StocksToTrade
Vyome Holdings Inc (HIND-Q) Stock Price and News - The Globe and Mail
Vyome Holdings Eyes Growth Amid Market Turbulence - timothysykes.com
Vyome stock soars after analyst values lead drug candidate at $1 billion - Investing.com Canada
Vyome Holdings Inc Stock (HIND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):